Status
Conditions
About
OBJECTIVES: I. Compare growth hormone (GH) levels at baseline and after glucose suppression measured with both a polyclonal radioimmunoassay and a highly sensitive immunoradiometric assay (IRMA) in patients with acromegaly and normal volunteers.
II. Measure the levels of IGF-I and its binding protein, IGFBP-3, in these cohorts.
III. Determine any correlation between levels of IGF-I and IGFBP-3 and GH suppressibility as assessed by sensitive IRMA.
IV. Determine if patients who demonstrate biochemical features of mild GH excess are at risk for progression to active disease.
Full description
PROTOCOL OUTLINE: Blood samples are collected and assessed for growth hormone and IGF-I by polyclonal radioimmunoassay (RIA) and immunoradiometric assay (IRMA). Growth hormone is measured at baseline and 60, 90, and 120 minutes after a 100 g glucose drink. Serum glucose is measured at baseline and at 2 hours post dextrose administration by the glucose hexokinase method.
Clinical scores are determined for headache, perspiration, fatigue, joint pain, and acne.
Exams and tests may be repeated every 6 months for 2 years.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnosis of acromegaly and treated with transsphenoidal surgery
Biochemically and histologically confirmed growth hormone secreting tumor
OR
Healthy volunteers
--Prior/Concurrent Therapy--
Surgery:
Other: At least 1 month since prior bromocriptine or octreotide
--Patient Characteristics--
Performance status: Ambulatory
Hepatic: No active hepatic disease
Renal: No active renal disease
Other:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal